Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis

被引:110
作者
Hanai, H
Watanabe, F
Yamada, M
Sato, Y
Takeuchi, K
Iida, T
Tozawa, K
Tanaka, T
Maruyama, Y
Matsushita, I
Iwaoka, Y
Kikuch, K
Saniabadi, AR
机构
[1] Hamamatsu Univ Sch Med, Dept Med, Hamamatsu, Shizuoka, Japan
[2] Fujueda Gen Hosp, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Med Ctr, Hamamatsu, Shizuoka, Japan
[4] Seirei Gen Hosp, Hamamatsu, Shizuoka, Japan
[5] Natl Tosei Hosp, Nagaizumi, Shizuoka, Japan
[6] Japan Immunores Labs, Takasaki, Gumma, Japan
关键词
ulcerative colitis; prednisolone; corticosteroid-dependent ulcerative colitis; granulocyte- and monocyte-adsorptive apheresis; steroid sparing;
D O I
10.1159/000080079
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aim: Active ulcerative colitis (UC) is often associated with increased peripheral granulocytes and monocytes/macrophages which show activation behavior and prolonged survival time. Further, mucosal granulocyte level parallels intestinal inflammation and can predict UC relapse. Accordingly, our aim was to see if adsorptive granulocyte/monocyte apheresis (GMA) can promote remission and spare steroid in patients with steroid-dependent (SD) UC. Methods: 69 SD patients, at the time of relapse, were randomly assigned to groups I (n = 46) and II (n = 23). The mean dose of prednisolone (PSL) was 12 mg/day/patient, CAI (clinical activity index) 9.2 in both groups. Group I patients were given up to 11 GMA sessions over 10 weeks with Adacolumn; in group II, the mean dose of PSL was increased to 30 mg/day/patient. Results: At week 12, 83% of group I and 65% of group II patients were in remission, CAI in group I was 1.7 (p < 0.001) and in group II, 2.5 (p < 0.001). Further, during the 12 weeks of treatment, the cumulative amount of PSL received per patient was 1,157 mg in group I and 1,938 mg in group II (p = 0.001). Conclusions: GMA appeared to be an effective adjunct to standard drug therapy of moderately severe UC by promoting remission and sparing steroids. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:36 / 44
页数:9
相关论文
共 52 条
[1]  
Allison MC, 1998, INFLAMMATORY BOWEL D
[2]  
BABB RR, 1988, J CLIN GASTROENTEROL, V10, P365
[3]  
BJARNASON I, 1994, INFLAMM BOWEL DIS, P53
[4]   Neutrophil apoptosis is delayed in patients with inflammatory bowel disease [J].
Brannigan, AE ;
O'Connell, PR ;
Hurley, H ;
O'Neill, A ;
Brady, HR ;
Fitzpatrick, JM ;
Watson, RWG .
SHOCK, 2000, 13 (05) :361-366
[5]   THE PRODUCTION OF CYTOKINES BY POLYMORPHONUCLEAR NEUTROPHILS [J].
CASSATELLA, MA .
IMMUNOLOGY TODAY, 1995, 16 (01) :21-26
[6]   Influence of disease site and activity on peripheral neutrophil function in inflammatory bowel disease [J].
D'Odorico, A ;
D'Inca, R ;
Mestriner, C ;
Di Leo, V ;
Ferronato, A ;
Sturniolo, GC .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (08) :1594-1600
[7]  
DARRIGO C, 1995, CLIN EXP IMMUNOL, V100, P173
[8]   A regulatory role for Fcγ receptors CD16 and CD32 in the development of murine B cells [J].
de Andres, B ;
Mueller, AL ;
Verbeek, S ;
Sandor, M ;
Lynch, RG .
BLOOD, 1998, 92 (08) :2823-2829
[9]   Seeing the wood for the trees: The forgotten role of neutrophils in rheumatoid arthritis [J].
Edwards, SW ;
Hallett, MB .
IMMUNOLOGY TODAY, 1997, 18 (07) :320-324
[10]   Inflammatory bowel disease: Etiology and pathogenesis [J].
Fiocchi, C .
GASTROENTEROLOGY, 1998, 115 (01) :182-205